Synergistic effects of olaparib combined with < em > ERCC1 < /em > on the sensitivity of cisplatin in non-small cell lung cancer
In conclusion, olaparib combined with ERCC1 expression may enhance the sensitivity of cisplatin in NSCLC. These findings may provide novel insight for the improvement of platinum drug sensitivity and treatment of NSCLC.PMID:33747222 | PMC:PMC7967929 | DOI:10.3892/ol.2021.12626
Source: Oncology Letters - Category: Cancer & Oncology Authors: Kejie Xie Xiaoyan Ni Shanmei Lv Guozhong Zhou Honger He Source Type: research
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | Lung Cancer | Non-Small Cell Lung Cancer | Study